Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

hu14.18–IL-2 (IC) is an immunocytokine consisting of human IL-2 linked to hu14.18 mAb, which recognizes the GD2 disialoganglioside. Phase 2 clinical trials of i.v. hu14.18–IL-2 (i.v.-IC) in neuroblastoma and melanoma are underway and have already demonstrated activity in neuroblastoma. We showed pre...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yang, Richard K., Kalogriopoulos, Nicholas A., Rakhmilevich, Alexander L., Ranheim, Erik A., Seo, Songwon, Kim, KyungMann, Alderson, Kory L., Gan, Jacek, Reisfeld, Ralph A., Gillies, Stephen D., Hank, Jacquelyn A., Sondel, Paul M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AAI 2012
Soggetti:
Clinical Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3424361/
https://ncbi.nlm.nih.gov/pubmed/22844125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1200934
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi